
Oncology firms Oncternal and Tokalas merge
Executive Summary
Cancer drug development firms Oncternal Therapeutics Inc. and Tokalas Inc. have merged into one entity which will carry the Oncternal name, and be led by Tokalas CEO Dr. James Breitmeyer. Financial details were not disclosed.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice